Market Overview

ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--

ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:

  • Lazard Capital Markets 9th Annual Healthcare Conference
    3:00 pm ET on November 14, 2012 in New York, NY
    Presenter: Gregory Perry, Executive Vice President and CFO
  • Jefferies 2012 Global Healthcare Conference in London
    10:00 am GMT (5:00 am ET) on November 15, 2012 in London, England
    Presenter: Daniel Junius, President and CEO

A webcast of each presentation can be accessed live through the “Investor Information” section of the Company's website, www.immunogen.com; a replay of each presentation will be available at the same location for one week.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies, potent cancer-cell killing agents and engineered linkers. The Company's TAP technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-killing agents specifically to tumor cells. There are now ten TAP compounds in clinical development, of which three are wholly owned by the Company. ImmunoGen's collaborative partners include Amgen, Bayer HealthCare, Biotest, Lilly, Novartis, Roche, and Sanofi. Marketing applications for trastuzumab emtansine (T-DM1), the most advanced compound using ImmunoGen's TAP technology, have been submitted in the US and Europe. Roche is developing this compound under an agreement between ImmunoGen and Genentech, a member of the Roche Group. More information about ImmunoGen can be found at www.immunogen.com.

Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
info@immunogen.com

 

Around the Web, We're Loving...

Get Benzinga's Newsletters